MET and thyroid gland carcinoma: Indeed, non-MET related effects of crizotinib were reported to contribute to the cell-cycle arrest and cytotoxicity observed in thyroid cancer cells [52] and inhibition of other RTKs, independently of ALK expression and activity, was recently observed in RMS cells [11].